Bispecifics spring ahead at this year’s ASH, SITC
First-in-human results at fall conferences reveal rapid expansion in the target space for bispecifics
The target space for bispecific antibodies is rapidly expanding, and early clinical data are on display at ASH and SITC.
Bispecific antibodies are starting to diverge from CAR Ts as they venture into new targets and indications in the clinic.
First-generation T cell-engaging bispecific antibodies have mirrored the trajectory of CAR T cell therapies for years, using the same CD19, CD20 and BCMA targets to draw T cells to destroy B cell malignancies.
With a simpler format for manufacturing and delivery than the cell therapies, interest in bispecifics has been ticking up at major medical conferences each year — and this year represents a turning point.
Interest is exploding, and companies are generating clinical data in new target spaces that CAR Ts haven’t yet touched. They’re also exploring next-generation bispecific constructs with new functionalities beyond engaging T cells as they transition the modality into solid tumors.
BioCentury’s analysis of the abstracts released ahead of the American Society of Hematology (ASH) virtual meeting that kicks off on Dec. 5 and the Society for Immunotherapy of Cancer (SITC) virtual meeting held last month finds that bispecific antibodies represent 21% of the new therapies sharing clinical data for the first time,